ARD:基线可溶性免疫检查点与诱导缓解后 PR3-ANCA 血管炎复发风险的关联

2022-09-13 MedSci原创 MedSci原创

当 sLag-3 浓度低而 sCD27 浓度高时,接受利妥昔单抗治疗的AAV患者获得缓解的频率较低。基线时较高浓度的 sTim-3、sCD27 和 sBTLA 可预测接受利妥昔单抗治疗的患者复发

目的该研究调查了可溶性免疫检查点 (sICPs) 是否可以预测抗中性粒细胞胞质抗体 (ANCA) 相关血管 (AAV) 患者的治疗耐药性、复发和感染。

方法:通过对蛋白酶 3 (PR3) 或髓过氧化物酶 (MPO)-ANCA 血管炎患者的免疫吸附测定法测量 RAVE 试验期间获得的可用样本的血浆 sICP 浓度,并与临床结果、一组生物标志物和现成的流式细胞术数据进行侧重于 T 细胞亚群的分析。对数秩检验用于评估生存益处,并使用 Yeldons J 计算标记分子的最佳截止值。

结果:对基线 189 份血浆样本的分析显示,与 PR3-ANCA 血管炎患者相比(n =127),MPO-ANCA血管炎患者(n=62)具有更高浓度的Tim-3, sCD27, sLag-3, sPD-1和sPD-L2在接受利妥昔单抗诱导治疗的患者 (n=95) 中,较低的可溶性 (s)Lag-3 (<90pg/mL) 和较高的 sCD27 (>3000pg/mL) 联合预测治疗失败 6 个月时达到缓解的利妥昔单抗组 73 名患者中有 24 名(32.9%)在随访期间复发。在该亚组中,sTim-3 (>1200pg/mL)sCD27 (>1250pg/mL) sBTLA (>1000pg/mL) 的高基线值与持续缓解和感染并发症相关。这些发现无法在随机接受环磷酰胺/硫唑嘌呤的 94 名患者中重复。

结论:当 sLag-3 浓度低而 sCD27 浓度高时,接受利妥昔单抗治疗的 AAV 患者获得缓解的频率较低。基线时较高浓度的 sTim-3sCD27 sBTLA 可预测接受利妥昔单抗治疗的患者复发这些结果需要确认,但可能有助于 AAV 的个性化治疗方法。 

出处:Gamerith G, Mildner F, Merkel PA, et al. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann Rheum Dis. 2022 Aug 16:annrheumdis-2022-222479. doi: 10.1136/ard-2022-222479. Epub ahead of print. PMID: 35973802.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905613, encodeId=fd6e190561399, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 26 02:03:54 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263283, encodeId=67671263283f1, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340623, encodeId=d98b134062377, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400826, encodeId=fa1514008267a, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905613, encodeId=fd6e190561399, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 26 02:03:54 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263283, encodeId=67671263283f1, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340623, encodeId=d98b134062377, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400826, encodeId=fa1514008267a, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905613, encodeId=fd6e190561399, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 26 02:03:54 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263283, encodeId=67671263283f1, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340623, encodeId=d98b134062377, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400826, encodeId=fa1514008267a, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905613, encodeId=fd6e190561399, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Jan 26 02:03:54 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263283, encodeId=67671263283f1, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340623, encodeId=d98b134062377, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400826, encodeId=fa1514008267a, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Sep 14 02:03:54 CST 2022, time=2022-09-14, status=1, ipAttribution=)]
    2022-09-14 一叶知秋

相关资讯

生物制剂停用后复发的原因及对策

因此即便使用过生物制剂这种“特效药”,病情依旧复发,强直患者也应鼓足信心,规范治疗,终能达到理想的效果。

CMI:中国东部地区肺结核再感染率与复发率

我国东部地区肺结核治疗后前两年,内源性复发明显多于外源性再感染。

IBD: 克罗恩病患者术后早期生物治疗与较低的内镜复发率和长期结果改善相关

克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但多发于末端回肠和右半结肠。本病和慢性非特异性溃疡性结肠炎两者统称为炎症性肠病(IBD)。

IBD: 早期启动抗肿瘤坏死因子治疗可减少回盲部切除术后克罗恩病的术后复发

克罗恩病是一种原因不明的肠道炎症性疾病,在胃肠道的任何部位均可发生,但多发于末端回肠和右半结肠。本病和慢性非特异性溃疡性结肠炎两者统称为炎症性肠病(IBD)。

JNCI:惊人!复发在乳腺癌确诊32年后仍在继续!累计发生率达16%!

J Natl Cancer Inst:乳腺癌初次诊断后10-32年复发的发生率。